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inﬂammation.3 Fukui et al.4 also reported that serum
bilirubin levels were associated with microalbuminuria and
subclinical atherosclerosis in patients with type 2 diabetes.
This letter by Zelle et al.1 further supported the relationship
between serum bilirubin and diabetic nephropathy in a
case–control study.
In the letter regarding the paper by Fukui et al.,4 Kassimatis
and Moutzouris5 claimed that it was unwarranted to discuss the
potential preventive and therapeutic application of bilirubin
or its diagnostic utility as a new risk factor for diabetic
nephropathy.5 In fact, these association studies do not
necessarily implicate the causative role of bilirubin in the
development of diabetic nephropathy. Therefore, we investi-
gated whether bilirubin may protect against diabetic nephro-
pathy in experimental animals in our article.2
Prospective studies are needed to conﬁrm its diagnostic
utility as a risk factor for diabetic nephropathy. In addition,
we agree that further intervention studies are needed to
explore the possibilities of compounds with similar properties
to bilirubin, which may represent a new class of therapeutic
agents that could protect against the development of diabetic
nephropathy.
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Circulating angiopoietin-1 could
be confounded by ex vivo
platelet activation
To the Editor: Reed et al.1 recently reported the relationship
between vascular endothelial growth factor (VEGF), angio-
poietin-1 (Ang-1), angiopoietin-2 (Ang-2), and renal as well
as cardiovascular disease progression in patients with
autosomal dominant polycystic kidney disease. Ang-1 and
Ang-2 are antagonistic ligands of their common receptor
Tie2. Unlike Ang-2, which is stored in endothelial cells, Ang-1
is not exclusively expressed by the vasculature; a high amount
of Ang-1 is also found in platelets. Thus, falsely high Ang-1
serum levels may result from ex vivo activation of platelets
upon clotting in serum tubes.2 The same is probably true
for vascular endothelial growth factor.3
Reed et al. found in the autosomal dominant polycystic
kidney disease population slightly elevated Ang-2 and
vascular endothelial growth factor (2–3 fold) serum levels
compared with those earlier reported in healthy individuals.
In contrast, mean Ang-1 levels in autosomal dominant
polycystic kidney disease patients were 35.52±21.03 ng/ml,
which is more than 20 times higher than the levels we and
others repeatedly detected in plasma from healthy subjects.2
However, we had earlier published similar falsely high Ang-1
levels in patients’ sera,4 unaware of the ex vivo release out
of platelets.
As Reed et al.1 performed all measurements in patients’
sera, one might question the validity and biological relevance
behind these ﬁndings (in particular the Ang-1/Ang-2 ratio).
In summary, it is possible that their results are confounded
by platelet-derived Ang-1.
A reliable way to quantify Ang-1 in a compartment-
speciﬁc way (i.e., the true circulatory fraction) would be
highly desirable for the design of future studies.
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The Authors Reply: We thank Drs David and Ku¨mpers1 for
their interest in our recent Kidney International publication.2
They point out that as angiopoietin-1 (Ang-1) is also found
in platelets, serum levels of Ang-1 may be falsely high due
to platelet activation. In our study, the most signiﬁcant
associations were between serum vascular endothelial growth
factor (VEGF) level with renal and cardiac structure (left
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ventricular mass index (LVMI)). When VEGF was added to the
model, the moderate relationship between serum Ang-1 with
total renal volume and LVMI was lost. Importantly, in our
study there was no association between serum VEGF level and
platelet counts in the autosomal dominant polycystic kidney
disease (ADPKD) study subjects. Moreover, there were no
signiﬁcant differences between levels of serum VEGF measured
in samples collected at baseline and after 18 months in 10
patients ruling out variable ex vivo platelet activation in our
samples. Paired serum and plasma VEGF levels have previously
been shown to correlate in control and colorectal cancer
subjects.3 Both plasma and platelet levels of VEGF and Ang-1
are elevated in hypertensive subjects,4 thus indicating the
apparent utility of measurement of both sera and plasma VEGF.
Although we concur that our results do not permit us to
comment upon the source of angiogenic growth factors, they do
impart new information regarding the relationship of VEGF
with renal and cardiac structure in ADPKD.
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Chronic renal failure induced
by lead
To the Editor: We read with interest the review article
by Evans and Elinder,1 who attempted to challenge the
well-established fact that lead exposure causes chronic renal
failure (CRF). Nevertheless, it seems that the authors missed
some important facts when citing our studies.2–4 In the
paper,1 the authors commented that the studies2–4 were
limited by not measuring glomerular ﬁltration rate (GFR) and
not adjusting for confounding factors (acidosis, inﬂammation,
and hyperparathyroidism). Furthermore, there is limited
knowledge and lack of validation of ethylenediaminetetra-
acetic acid (EDTA) test among CRF patients. These inter-
pretations are not entirely correct.
For example, we have reported3 that GFR improved
signiﬁcantly by the end of the 27th month in patients
receiving EDTA chelation therapy. The mean change in
GFR in the chelation group was 2.1±5.7ml/min, as
compared with 6.0±5.8ml/min in the controls
(Po0.001). The rate of decline in GFR in the chelation
group was also lower than that in the controls during the 24-
month period of repeated chelation therapy or placebo.
Anyway, we reckon that the studies2–4 were not adjusted for
the above-mentioned confounders, but we wonder if the
chronic kidney disease stage 3 of the studied population2–4
could cause any considerable acidosis, inﬂammation, or
hyperparathyroidism. In contrast, advanced-stage chronic
kidney disease or end-stage renal disease5 might be the
exception. Literature data on the validation of the EDTA test
among CRF patients are few, but we have demonstrated6 that
repeated chelation therapy slowed the progression of renal
insufﬁciency in non-diabetic patients with high normal-body
lead burden.
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The Authors Reply: We are pleased that Lin et al.1 have
read and commented on our mini review in Kidney
International 2 in which we challenge the often-repeated,
but not very well-founded, view that exposure to lead may
cause chronic renal failure (CRF) in adults. The ﬁnding of Lin
et al. that repeated infusions of ethylenediaminetetraacetic
acid (EDTA) in patients with reduced renal function (serum
creatinine 1.5–3.9mg/dl, estimated glomerular ﬁltration rate
(GFR) 18–56ml/min per 1.73m2) decrease the decline in
estimated renal function compared with controls is remark-
able, to say the least. We argue, however, that the GFR in
these studies was not actually measured, but estimated from
the serum creatinine concentration and creatinine clearance.
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